PubMed:9271588 JSONTXT

{"project":"jnlpba-st-training","denotations":[{"id":"T1","span":{"begin":30,"end":34},"obj":"protein"},{"id":"T2","span":{"begin":57,"end":71},"obj":"DNA"},{"id":"T3","span":{"begin":76,"end":85},"obj":"protein"},{"id":"T4","span":{"begin":176,"end":202},"obj":"cell_type"},{"id":"T5","span":{"begin":207,"end":211},"obj":"protein"},{"id":"T6","span":{"begin":217,"end":240},"obj":"protein"},{"id":"T7","span":{"begin":308,"end":326},"obj":"cell_type"},{"id":"T8","span":{"begin":404,"end":408},"obj":"protein"},{"id":"T9","span":{"begin":421,"end":442},"obj":"cell_type"},{"id":"T10","span":{"begin":465,"end":474},"obj":"protein"},{"id":"T11","span":{"begin":475,"end":495},"obj":"protein"},{"id":"T12","span":{"begin":581,"end":607},"obj":"DNA"},{"id":"T13","span":{"begin":683,"end":692},"obj":"protein"}],"text":"Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction.\nEpstein-Barr virus (EBV), an oncogenic human herpesvirus, binds to and infects normal human B lymphocytes via CD21, the CR2 complement receptor. Studies of the mechanisms that enable EBV to infect nonactivated, noncycling B cells provide compelling evidence for a sequence of events in which EBV binding to CD21 on purified resting human B cells rapidly activates the NF-kappaB transcription factor, which, in turn, binds to and mediates transcriptional activation of Wp, the initial viral latent gene promoter. Thus, EBV binding to its cellular receptor on resting B cells triggers an NF-kappaB-dependent intracellular signaling pathway which is required for infection."}

{"project":"pubmed-sentences-benchmark","denotations":[{"id":"S1","span":{"begin":0,"end":96},"obj":"Sentence"},{"id":"S2","span":{"begin":97,"end":241},"obj":"Sentence"},{"id":"S3","span":{"begin":242,"end":608},"obj":"Sentence"},{"id":"S4","span":{"begin":609,"end":767},"obj":"Sentence"}],"text":"Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction.\nEpstein-Barr virus (EBV), an oncogenic human herpesvirus, binds to and infects normal human B lymphocytes via CD21, the CR2 complement receptor. Studies of the mechanisms that enable EBV to infect nonactivated, noncycling B cells provide compelling evidence for a sequence of events in which EBV binding to CD21 on purified resting human B cells rapidly activates the NF-kappaB transcription factor, which, in turn, binds to and mediates transcriptional activation of Wp, the initial viral latent gene promoter. Thus, EBV binding to its cellular receptor on resting B cells triggers an NF-kappaB-dependent intracellular signaling pathway which is required for infection."}

{"project":"genia-medco-coref","denotations":[{"id":"C1","span":{"begin":30,"end":34},"obj":"NP"},{"id":"C2","span":{"begin":97,"end":121},"obj":"NP"},{"id":"C3","span":{"begin":123,"end":153},"obj":"NP"},{"id":"C4","span":{"begin":207,"end":211},"obj":"NP"},{"id":"C5","span":{"begin":213,"end":240},"obj":"NP"},{"id":"C6","span":{"begin":253,"end":267},"obj":"NP"},{"id":"C7","span":{"begin":268,"end":272},"obj":"NP"},{"id":"C8","span":{"begin":280,"end":283},"obj":"NP"},{"id":"C9","span":{"begin":359,"end":379},"obj":"NP"},{"id":"C10","span":{"begin":383,"end":388},"obj":"NP"},{"id":"C11","span":{"begin":404,"end":408},"obj":"NP"},{"id":"C12","span":{"begin":461,"end":495},"obj":"NP"},{"id":"C13","span":{"begin":497,"end":502},"obj":"NP"},{"id":"C14","span":{"begin":565,"end":567},"obj":"NP"},{"id":"C15","span":{"begin":569,"end":607},"obj":"NP"},{"id":"C16","span":{"begin":615,"end":618},"obj":"NP"},{"id":"C17","span":{"begin":630,"end":633},"obj":"NP"},{"id":"C18","span":{"begin":680,"end":734},"obj":"NP"},{"id":"C19","span":{"begin":735,"end":740},"obj":"NP"}],"relations":[{"id":"R1","pred":"coref-appos","subj":"C3","obj":"C2"},{"id":"R2","pred":"coref-ident","subj":"C4","obj":"C1"},{"id":"R3","pred":"coref-appos","subj":"C5","obj":"C4"},{"id":"R4","pred":"coref-relat","subj":"C7","obj":"C6"},{"id":"R5","pred":"coref-ident","subj":"C8","obj":"C2"},{"id":"R6","pred":"coref-relat","subj":"C10","obj":"C9"},{"id":"R7","pred":"coref-ident","subj":"C11","obj":"C4"},{"id":"R8","pred":"coref-relat","subj":"C13","obj":"C12"},{"id":"R9","pred":"coref-appos","subj":"C15","obj":"C14"},{"id":"R10","pred":"coref-ident","subj":"C16","obj":"C8"},{"id":"R11","pred":"coref-pron","subj":"C17","obj":"C16"},{"id":"R12","pred":"coref-relat","subj":"C19","obj":"C18"}],"text":"Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction.\nEpstein-Barr virus (EBV), an oncogenic human herpesvirus, binds to and infects normal human B lymphocytes via CD21, the CR2 complement receptor. Studies of the mechanisms that enable EBV to infect nonactivated, noncycling B cells provide compelling evidence for a sequence of events in which EBV binding to CD21 on purified resting human B cells rapidly activates the NF-kappaB transcription factor, which, in turn, binds to and mediates transcriptional activation of Wp, the initial viral latent gene promoter. Thus, EBV binding to its cellular receptor on resting B cells triggers an NF-kappaB-dependent intracellular signaling pathway which is required for infection."}

{"project":"GENIAcorpus","denotations":[{"id":"T1","span":{"begin":0,"end":18},"obj":"virus"},{"id":"T2","span":{"begin":30,"end":34},"obj":"protein_molecule"},{"id":"T3","span":{"begin":57,"end":71},"obj":"DNA_domain_or_region"},{"id":"T4","span":{"begin":76,"end":85},"obj":"protein_complex"},{"id":"T5","span":{"begin":97,"end":115},"obj":"virus"},{"id":"T6","span":{"begin":117,"end":120},"obj":"virus"},{"id":"T7","span":{"begin":126,"end":153},"obj":"virus"},{"id":"T8","span":{"begin":176,"end":202},"obj":"cell_type"},{"id":"T9","span":{"begin":207,"end":211},"obj":"protein_molecule"},{"id":"T10","span":{"begin":217,"end":240},"obj":"protein_molecule"},{"id":"T11","span":{"begin":280,"end":283},"obj":"virus"},{"id":"T12","span":{"begin":308,"end":326},"obj":"cell_type"},{"id":"T13","span":{"begin":389,"end":392},"obj":"virus"},{"id":"T14","span":{"begin":404,"end":408},"obj":"protein_molecule"},{"id":"T15","span":{"begin":421,"end":442},"obj":"cell_type"},{"id":"T16","span":{"begin":465,"end":474},"obj":"protein_complex"},{"id":"T17","span":{"begin":475,"end":495},"obj":"protein_family_or_group"},{"id":"T18","span":{"begin":581,"end":607},"obj":"DNA_domain_or_region"},{"id":"T19","span":{"begin":615,"end":618},"obj":"virus"},{"id":"T20","span":{"begin":683,"end":692},"obj":"protein_complex"}],"text":"Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction.\nEpstein-Barr virus (EBV), an oncogenic human herpesvirus, binds to and infects normal human B lymphocytes via CD21, the CR2 complement receptor. Studies of the mechanisms that enable EBV to infect nonactivated, noncycling B cells provide compelling evidence for a sequence of events in which EBV binding to CD21 on purified resting human B cells rapidly activates the NF-kappaB transcription factor, which, in turn, binds to and mediates transcriptional activation of Wp, the initial viral latent gene promoter. Thus, EBV binding to its cellular receptor on resting B cells triggers an NF-kappaB-dependent intracellular signaling pathway which is required for infection."}